• No results found

VU Research Portal

N/A
N/A
Protected

Academic year: 2021

Share "VU Research Portal"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

VU Research Portal

Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors

Xu, G.

2016

document version

Publisher's PDF, also known as Version of record

Link to publication in VU Research Portal

citation for published version (APA)

Xu, G. (2016). Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in

BRCA1-mutated mouse mammary tumors.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain

• You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

(2)

205

CURRICULUM VITAE

Guotai Xu was born on August 22, 1985 in Taihe, Anhui, China. After he received his Bachelor of Engineering degree in Pharmaceutical Sciences from the Pharmacy College at Shandong University. In 2006, he joined the Master’s program on Microbiology and Pharmaceutical Sciences at the same College, where he worked on lung cancer gene therapy and also toll-like receptor mediated innate immunity under the supervision of Prof. Zhigang Tian. In 2009, he received his Master of Medicine degree at Shandong University. In October 2009, he joined the group of Prof. dr. Sven Rottenberg and Prof. dr. Piet Borst at the Netherlands Cancer Institute (NKI), where he investigated mechanisms of PARPi resistance in BRCA1-related mouse mammary tumors.

Referenties

GERELATEERDE DOCUMENTEN

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. PARP-1 and Ku compete

b, Quantification of RAD51 foci in KB1P-G3 cells (with or without REV7 depletion) transfected with an empty vector (GFP) or vectors containing mouse or human

We observed this phenomenon by immunofluorescence of endogenous HELB in MEFs, where HELB loses its nuclear enrichment in cells that are undergoing DNA replication (Figure 6A and

In addition, we found that XRN2 loss also causes PARP inhibitor (PARPi) resistance of Brca1; p53-deficient mouse mammary tumor cells both in vitro and in vivo.. We aim

In particular, the groups of Jos Jonkers and Andre Nussenzweig found that loss of 53BP1 enhanced end resection at DSBs and restored BRCA1- independent HR,

In Chapter 2, we report that loss of REV7 (also known as MAD2L2) in mouse and human cells rescues CTIP-dependent end resection of DSBs in BRCA1- deficient

Consistent met de nieuwe rol van HELB als antagonist van resectie, leidt verlies van HELB ook tot gedeeltelijk herstel van HR en resistentie tegen PARP remming

Jaspers, Wendy Sol, Ariena Kersbergen, Andreas Schlicker, Charlotte Guyader, Guotai Xu, Lodewyk Wessels, Piet Borst, Jos Jonkers, Sven Rottenberg. PARP Inhibitors for Cancer